By Peter Loftus
Moderna shares fell 3% in premarket trading after the company swung to a quarterly loss, as fading demand for its Covid-19 vaccine hurts sales.
The company reported a net loss of $1.1 billion, or $2.91 per share, which included costs to end a contract manufacturing deal and an inventory writedown. A year earlier, Moderna earned $217 million, or 55 cents a share.
The company's fourth-quarter sales slid 65% to $966 million.
Moderna's share of the Covid-19 vaccine market declined in 2024, and overall vaccination rates were somewhat lower than the year before, Chief Financial Officer Jamey Mock said in an interview.
Moderna is in cost-cutting mode as revenue declines, but the company hopes to turn things around with newer products.
It is trying to broaden usage of its new respiratory syncytial virus vaccine, and has applied for U.S. regulatory approval of a next-generation Covid vaccine and a combination Covid-influenza shot, with decisions expected later this year.
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
February 14, 2025 08:18 ET (13:18 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。